US 12336990
Treatment of prostate cancer
granted A61KA61K31/4166A61K31/501
Quick answer
US patent 12336990 (Treatment of prostate cancer) held by Takeda Pharmaceutical Company Limited expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K31/4166, A61K31/501, A61K31/513, A61K31/519